First Trust Direct Indexing’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-4,708
| Closed | -$542K | – | 589 |
|
|
2024
Q3 | $542K | Buy |
4,708
+264
| +6% | +$30.4K | 0.03% | 519 |
|
|
2024
Q2 | $612K | Buy |
4,444
+314
| +8% | +$43.2K | 0.04% | 449 |
|
|
2024
Q1 | $570K | Buy |
4,130
+933
| +29% | +$129K | 0.04% | 439 |
|
|
2023
Q4 | $421K | Buy |
3,197
+1,017
| +47% | +$134K | 0.04% | 489 |
|
|
2023
Q3 | $245K | Buy |
+2,180
| New | +$245K | 0.03% | 579 |
|
|
2023
Q1 | – | Sell |
-1,867
| Closed | -$223K | – | 713 |
|
|
2022
Q4 | $223K | Buy |
+1,867
| New | +$223K | 0.03% | 592 |
|
|
2021
Q1 | – | Sell |
-942
| Closed | -$90K | – | 766 |
|
|
2020
Q4 | $90K | Buy |
+942
| New | +$90K | 0.02% | 546 |
|